AORT logo

Artivion Stock Price

Symbol: NYSE:AORTMarket Cap: US$1.5bCategory: Healthcare

AORT Share Price Performance

Recent AORT News & Updates

No updates

Artivion, Inc. Key Details

US$390.1m

Revenue

US$140.7m

Cost of Revenue

US$249.4m

Gross Profit

US$270.8m

Other Expenses

-US$21.3m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 07, 2025
Earnings per share (EPS)
-0.45
Gross Margin
63.94%
Net Profit Margin
-5.47%
Debt/Equity Ratio
107.0%

Artivion, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About AORT

Founded
1984
Employees
1600
CEO
James Mackin
WebsiteView website
artivion.com

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves, and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures for mitral chordal replacement; and pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 10.7%
  • 1 Year: 17.5%
  • Year to Date: 5.9%
The market has dropped by 18% in the last 7 days, with the Financials sector leading declines. In contrast to the last week, the market is actually up 18% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading